Study aims to predict diabetes risk from common transplant drug
NCT ID NCT03640026
First seen Apr 14, 2026 · Last updated Jun 22, 2026 · Updated 12 times
Summary
This study looked at how the drug tacrolimus, often used after kidney transplants, affects blood sugar and insulin in people with kidney failure who are waiting for a transplant. Researchers wanted to find early signs of diabetes risk so doctors could adjust treatment. The study was terminated early and involved 61 adults on hemodialysis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY FAILURE, CHRONIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Hospitalier Départemental Vendée
La Roche-sur-Yon, France
-
Centre Hospitalier Universitaire Nantes
Nantes, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tacrolimus
What this could lead to
If successful, this could help doctors identify patients at risk for tacrolimus-induced diabetes before kidney transplant, allowing them to choose safer immunosuppressants.
What could go wrong
This was a small, terminated Phase 4 study with only 61 participants. Results may not be conclusive or widely applicable.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.